HCC

A 77-year-old woman presented to her primary care physician complaining of abdominal pain and fatigue. Ghassan K. Abou-Alfa, MD, discussed the case with a group of physicians.

Most patients with advanced HCC have resistance to PD-1 monotherapy. In other cancers, response to PD-1 inhibitors has been associated with an inflamed microenvironment with effector T cells and active IFN-α signaling.

In an interview with during the 2021 International Liver Cancer Association Annual Conference, David J. Pinato, MD discussed combination strategies in hepatocellular carcinoma, how to manage associated toxicities, and how safety profiles can help to inform treatment decisions for this patient population.

Phase 1 data indicate that ADP-A2AFP SPEAR T cells are effective and tolerable in patients with advanced hepatocellular carcinoma.

In CheckMate040, single-agent nivolumab achieved durable responses in patients with advanced hepatocelluar carcinoma.

Richard S. Finn, MD and a group of peers discusses that case of a 77-year-old woman who presented to her primary care physician complaining of abdominal pain and fatigue.

Pembrolizumab led to improvement in overall survival compared to placebo in patients with advanced hepatocellular carcinoma previously treated with sorafenib.

During a Targeted Oncology Case-Based Roundtable event, Mark Yarchoan, MD, moderates a discussion about a 77-year-old woman with Child Pugh B and C hepatocellular carcinoma.

The FDA has granted a breakthrough device designation to the NovoTTF-200T System, a tumor treating fields delivery system, for the treatment of unresectable or metastatic liver cancer.

In an interview, Amaia Lujambio, MD discussed the diversity of genomic alterations in hepatocellular and advanced in molecular testing that could shape future understanding of the disease.

A study has shown that high interferon signaling and expression of MHC-II related genes can predict response to therapy is patients with advanced heptocellular carcinoma being treated for the first time.

Atezolizumab given in combination with bevacizumab led to an improvement in overall survival compared with sorafenib in patients with albumin-bilirubin grade 1 hepatocellular carcinoma.

Efficacy and safety have been demonstrated with the combination of durvalumab with tremelimumab and transcatheter arterial chemoembolization or radiofrequency ablation in advanced hepatocellular carcinoma.

In an interview with Targeted Oncology™, Ming Zhao, MD, discussed how the efficacy of HAIC-FO for the treatment of HCC compares to sorafenib as investigated in the FOHAIC-1 clinical trial.

In an interview with Targeted Oncology, Ghassan K. Abou-Alfa, MD, discusses the efficacy of tislelizumab in HCC in greater detail, along with safety and the agent’s mechanism of action. 

The Oncoguard Liver liquid biopsy test has demonstrated a high sensitivity and specificy for the detection of hepatocellular carcinoma (HCC), including in patients with early-stage HCC.

The indication for nivolumab as a single agent for the treatment of hepatocellular carcinoma in patients previously treated with sorafenib has been withdrawn from the US market.

Sintilimab in combination with the bevacizumab biosimilar, IBI305, is associated with a significant overall survival and progression-free survival benefit over sorafenib in the first-line setting for the treatment of Chinese patients with unresectable, hepatitis B virus-associated hepatocellular carcinoma.

A network meta-analysis looking at 4 studies that assessed atezolizumab/bevacizumab compared to lenvatinib showed there was not a statistically significant improvement for patients with unresectable hepatocellular carcinoma.

In an interview with Targeted Oncology, HEPANOVA EF-30 investigator, Eleni Gikka, MD, provided insight into the use of TTFields in combination with standard of care therapy for patients with advanced hepatocellular carcinoma.

A phase 2 trial of tislelizumab and another trial of Tumor Treating Fields accompanied by sorafenib are filling unmet needs in advanced hepatocellular carcinoma, although more data are still needed in this space.

Patients with unresectable hepatocellular carcinoma with Child-Pugh class B liver function experienced a similar tumor size reduction as their Child-Pugh class A counterparts, all treated with lenvatinib, according to a post-hoc analysis of the phase 3 REFLECT study.

As June is Cancer Immunotherapy Month, Mehmet Akce, MD, discusses the future of immunotherapy in HCC in an interview with Targeted Oncology.

The combination of cabozantinib and atezolizumab demonstrated improvement in both progression-free and overall survival compared with sorafenib, in patients with untreated advanced hepatocellular carcinoma.

New published data from a phase 2/3 trial shows the increased survival benefit of PD-1 inhibitor sintililmab and bevacizumab biosimilar IBI305 in the frontline setting for patients with metastatic HCC.